Amgen and AstraZeneca Combination Therapy Improves Lung Cancer Survival

A clinical trial demonstrated that Amgen's Imdelltra, when combined with AstraZeneca's immunotherapy Imfinzi, significantly extended survival for patients with extensive-stage small cell lung cancer. The combination reduced the risk of death by 58% compared to Imfinzi alone, with patients living a median of 21.1 months versus 12.7 months. These results, published in the New England Journal of Medicine, suggest a notable advancement in treatment options for this aggressive cancer.